REGENXBIO Inc. (RGNX)
NASDAQ: RGNX · Real-Time Price · USD
11.34
+0.42 (3.85%)
At close: Oct 13, 2025, 4:00 PM EDT
11.13
-0.21 (-1.85%)
Pre-market: Oct 14, 2025, 4:42 AM EDT
REGENXBIO Revenue
REGENXBIO had revenue of $21.36M in the quarter ending June 30, 2025, a decrease of -4.20%. This brings the company's revenue in the last twelve months to $155.78M, up 74.95% year-over-year. In the year 2024, REGENXBIO had annual revenue of $83.33M, down -7.66%.
Revenue (ttm)
$155.78M
Revenue Growth
+74.95%
P/S Ratio
3.72
Revenue / Employee
$441,309
Employees
353
Market Cap
572.83M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 83.33M | -6.91M | -7.66% |
| Dec 31, 2023 | 90.24M | -22.48M | -19.94% |
| Dec 31, 2022 | 112.72M | -357.62M | -76.03% |
| Dec 31, 2021 | 470.35M | 315.78M | 204.30% |
| Dec 31, 2020 | 154.57M | 119.33M | 338.70% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
RGNX News
- 4 days ago - REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting - PRNewsWire
- 7 days ago - REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD - PRNewsWire
- 14 days ago - REGENXBIO Announces Presentation at the World Muscle Society - PRNewsWire
- 5 weeks ago - Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome - Seeking Alpha
- 5 weeks ago - REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript - Seeking Alpha
- 5 weeks ago - Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome - Seeking Alpha
- 5 weeks ago - REGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS II - PRNewsWire
- 6 weeks ago - REGENXBIO to Participate in Upcoming Investor Conferences - PRNewsWire